Laboratoire XO secures backing of Novalpina Capital
Novalpina Capital has closed the acquisition of French specialty pharma business Laboratoire XO.XO focuses on prescription drugs treating chronic diseases that require prescription or recommendation by a physician or pharmacist. Its core product focus is selling and marketing ‘princeps’ – original drug brands – with defensible market positions and strong